These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 11901360)
1. Alpha2-macroglobulin exon 24 (Val-1000-Ile) polymorphism is not associated with late-onset sporadic Alzheimer's dementia in the Hungarian population. Janka Z; Juhász A; Rimanóczy A; Boda K; Márki-Zay J; Palotás M; Kuk I; Zöllei M; Jakab K; Kálmán J Psychiatr Genet; 2002 Mar; 12(1):49-54. PubMed ID: 11901360 [TBL] [Abstract][Full Text] [Related]
2. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Zappia M; Manna I; Serra P; Cittadella R; Andreoli V; La Russa A; Annesi F; Spadafora P; Romeo N; Nicoletti G; Messina D; Gambardella A; Quattrone A Arch Neurol; 2004 Mar; 61(3):341-4. PubMed ID: 15023809 [TBL] [Abstract][Full Text] [Related]
3. Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans. Jhoo JH; Kim KW; Lee DY; Lee KU; Lee JH; Kim SY; Youn JY; Youn JC; Woo JI J Neurol Sci; 2001 Feb; 184(1):21-5. PubMed ID: 11231028 [TBL] [Abstract][Full Text] [Related]
4. Alpha2-macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese. Sodeyama N; Yamada M; Itoh Y; Suematsu N; Matsushita M; Otomo E; Mizusawa H Neurology; 2000 Jan; 54(2):443-6. PubMed ID: 10668711 [TBL] [Abstract][Full Text] [Related]
5. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. Blennow K; Ricksten A; Prince JA; Brookes AJ; Emahazion T; Wasslavik C; Bogdanovic N; Andreasen N; Båtsman S; Marcusson J; Nägga K; Wallin A; Regland B; Olofsson H; Hesse C; Davidsson P; Minthon L; Jansson A; Palmqvist L; Rymo L J Neural Transm (Vienna); 2000; 107(8-9):1065-79. PubMed ID: 11041282 [TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients. Zamani M; Mohammadi M; Zamani H; Tavasoli A Mol Neurobiol; 2016 Sep; 53(7):4521-8. PubMed ID: 26289409 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E promoter and alpha2-macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease. Chen L; Baum L; Ng HK; Chan LY; Sastre I; Artíga MJ; Valdivieso F; Bullido MJ; Chiu HF; Pang CP Neurosci Lett; 1999 Jul; 269(3):173-7. PubMed ID: 10454160 [TBL] [Abstract][Full Text] [Related]
8. Neither the tumor necrosis factor alpha-308 A/G polymorphism nor the alpha2-macroglobulin polymorphism was associated with late-onset Alzheimer's disease in the Chinese population. Zhang P; Yang Z; Wan CL; Zheng WD; Zhang CF; Li S; Lü ZP; Zheng CG; Jin F; Wang L Yi Chuan Xue Bao; 2004 Jan; 31(1):1-6. PubMed ID: 15468911 [TBL] [Abstract][Full Text] [Related]
9. Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. Mariani E; Seripa D; Ingegni T; Nocentini G; Mangialasche F; Ercolani S; Cherubini A; Metastasio A; Pilotto A; Senin U; Mecocci P J Neurol Sci; 2006 Sep; 247(2):187-91. PubMed ID: 16784755 [TBL] [Abstract][Full Text] [Related]
10. Genetic association of alpha2-macroglobulin polymorphisms with AD in southern Italy. Zappia M; Cittadella R; Manna I; Nicoletti G; Andreoli V; Bonavita S; Gambardella A; Quattrone A Neurology; 2002 Sep; 59(5):756-8. PubMed ID: 12221172 [TBL] [Abstract][Full Text] [Related]
11. Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease. Halimi G; Duplan L; Bideau C; Iniesta D; Berthézène P; Oddoze C; Verdier JM; Michel B; Bergé-Lefranc JL Neuroreport; 2000 Nov; 11(16):3599-601. PubMed ID: 11095526 [TBL] [Abstract][Full Text] [Related]
13. Association of polymorphisms in the LRP1 and A2M genes with Alzheimer's disease in the northern Chinese Han population. Yuan Q; Wang F; Xue S; Jia J J Clin Neurosci; 2013 Feb; 20(2):253-6. PubMed ID: 23186781 [TBL] [Abstract][Full Text] [Related]
14. Alpha2-macroglobulin polymorphisms in Alzheimer's disease and dementia with Lewy bodies. Singleton AB; Gibson AM; McKeith IG; Ballard CA; Perry RH; Ince PG; Edwardson JA; Morris CM Neuroreport; 1999 May; 10(7):1507-10. PubMed ID: 10380971 [TBL] [Abstract][Full Text] [Related]
15. Genetic association between alpha-2 macroglobulin and Japanese sporadic Alzheimer's disease. Shibata N; Ohnuma T; Takahashi T; Ohtsuka E; Ueki A; Arai H Neurosci Lett; 1999 Aug; 271(2):132-4. PubMed ID: 10477120 [TBL] [Abstract][Full Text] [Related]
16. Alpha-2-macroglobulin intronic polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. Kovács T; Cairns NJ; Lantos PL Neurosci Lett; 1999 Sep; 273(1):61-83. PubMed ID: 10505652 [TBL] [Abstract][Full Text] [Related]
17. Lack of association between alpha2-macroglobulin polymorphisms and Alzheimer's disease. Wang X; Luedecking EK; Minster RL; Ganguli M; DeKosky ST; Kamboh MI Hum Genet; 2001 Feb; 108(2):105-8. PubMed ID: 11281447 [TBL] [Abstract][Full Text] [Related]
18. The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Koster MN; Dermaut B; Cruts M; Houwing-Duistermaat JJ; Roks G; Tol J; Ott A; Hofman A; Munteanu G; Breteler MM; van Duijn CM; Van Broeckhoven C Neurology; 2000 Sep; 55(5):678-84. PubMed ID: 10980733 [TBL] [Abstract][Full Text] [Related]
19. A deletion polymorphism of alpha(2)-macroglobulin gene and cerebral amyloid angiopathy. Yamada M; Sodeyama N; Itoh Y; Suematsu N; Otomo E; Matsushita M; Mizusawa H Stroke; 1999 Nov; 30(11):2277-9. PubMed ID: 10548657 [TBL] [Abstract][Full Text] [Related]